A consolidated class action complaint has been filed against Johnson & Johnson and Janssen, L.P. alleging that the companies illegally market and promote their pharmaceutical, Risperdal, for "off-label" uses - that is, for uses not approved by the FDA.  The alleged scheme includes off-label promotion for indications such as dementia, Alzheimer's disease, depression, Obsessive-Compulsive Disorder, anxiety, sleep disorders, anger management, Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder and Tourette's Syndrome.

If you are a consumer who purchased Risperdal, with or without insurance reimbursement, and wish to discuss your possible legal remedies, or have other information regarding Risperdal that you would like to report, please submit a form, This email address is being protected from spam bots, you need Javascript enabled to view it or contact our Washington, D.C. office toll free at (877) 337-8000.

The consolidated complaint alleges that Johnson & Johnson and Janssen controlled, monitored and/or directed various marketing firms, physicians and ghostwriters to promote and disseminate - through sponsored events and publications - misleading messages about the efficacy relating to the off-label use of Risperdal.  The complaint also alleges that in 2006, approximately sixty-six percent of the prescriptions for Risperdal were for off-label use, helping to propel sales.  It is further alleged that although less expensive alternatives to Risperdal were available on the market, Johnson & Johnson and Janssen's scheme forced consumers to pay higher co-payments and out-of-pocket costs for Risperdal.   

Risperdal has been approved to treat schizophrenia in adults and adolescents ages 13-17 years; acute manic or mixed episodes of bipolar I disorder in adults; short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder in children and adolescents ages 10-17 years; and irritability associated with autistic disorder in children and adolescents ages 5-16 years.